Novel Treatment Advances and Approaches in the Management of Insomnia: Managed Care Considerations in an Evolving Management Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Insomnia

These are archives of live webinars held between October 23 and October 30, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These activities are valid from December 1, 2020 to December 1, 2022


This series is supported by an educational grant from Eisai

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. The dangers of insomnia can affect more than just a person’s mood as people and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.

Integrating the Latest Data and Guidelines in the Management of Insomnia: Utilizing New Therapies for Optimal Clinical and Economic Outcomes

1. Describe the clinical and economic impact of insomnia on quality of life and risk of psychiatric and physical illnesses
2. Examine treatment guidelines and differentiate current and newer treatments, including efficacy and safety considerations
3. Apply the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia
4. Examine the clinical data for the safety and efficacy profiles for pharmacologic therapies for the treatment of insomnia and untreated insomnia

Improving Patient Adherence and Quality of Life in Insomnia: Strategies for Managing Treatment Related Adverse Events Associated with Newer Therapies

1. Assess challenges to patient adherence and quality of life in insomnia
2. Explore strategies to monitor and manage adverse events associated with newer dual orexin receptor antagonists in insomnia in order to improve patient adherence and quality of life
3. Examine the clinical data for the safety profiles for pharmacologic therapies for the treatment of insomnia
4. Advance the long-term management of insomnia in provider and managed care settings through measures that facilitate at-risk patient monitoring, promote patient/provider education, and integrate newer therapies for optimal patient outcomes
5. Analyze the challenges associated with treatment and managing insomnia, including patient adherence and untreated insomnia

What Managed Care Needs to Know about New Therapies in the Management of Insomnia

1. Analyze the economic burden of insomnia and the impact of suboptimal management on outcomes
2. Review the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia
3. Explore costs associated with insomnia and patient population needs to identify potential management strategies
4. Apply formulary strategies to assist in appropriate treatment choices and stem the high healthcare utilization associated with insomnia
5. Assess the managed care considerations of new and emerging therapies, including dual orexin receptor antagonists, by exploring where these agents fit in the insomnia man